Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) saw some unusual options trading on Wednesday. Stock traders bought 66,895 call options on the stock. This is an increase of 81% compared to the typical daily volume of 37,032 call options.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks highlights BMY’s strong earnings‑surprise history and says the company currently shows the combinations that make another quarterly beat likely — this raises expectations for near‑term upside when results are released. Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Late‑stage Camzyos data: adolescent Phase 3 results met the primary endpoint with no new safety signals — a clear path to label expansion would increase addressable market for BMY’s cardiovascular franchise. Camzyos Adolescent Trial Success Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
• Positive Sentiment: Institutional interest: Ariel Global Fund re‑added BMY citing pipeline strength and attractive valuation — a sign of fundamental investor conviction that can support share price. Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation
• Neutral Sentiment: Market opportunity: Research reports project multi‑billion dollar growth in advanced renal cell carcinoma and broader kidney cancer drug markets over 2026–2030 — positive for long‑term TAM but not an immediate revenue driver. Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030
• Neutral Sentiment: Kidney cancer drugs market growth report underscores expanding demand where BMY competes — supportive background for franchise growth but incremental and multi‑year. Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030
• Neutral Sentiment: Corporate/CSR update: BMY marks a decade of programs to advance care in multiple myeloma — positive PR but limited short‑term stock impact. Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma
• Neutral Sentiment: Short‑term trading note: market writeups show the stock has risen recently but still lags broader market performance — suggests momentum but possible relative weakness. Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market
• Negative Sentiment: Analyst outlook mixed: coverage notes “mixed analyst sentiment” which can limit upside if analysts issue cautious revisions or downgrades after earnings or pipeline readouts. Bristol-Myers Squibb (BMY) faces mixed analyst sentiment despite strong momentum in healthcare industry

Bristol Myers Squibb Stock Performance

BMY stock traded up $1.14 during midday trading on Wednesday, reaching $61.79. The company had a trading volume of 6,529,121 shares, compared to its average volume of 13,440,122. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The stock has a 50 day moving average price of $59.03 and a 200 day moving average price of $52.45. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm has a market capitalization of $126.15 billion, a PE ratio of 17.94, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Hedge Funds Weigh In On Bristol Myers Squibb

A number of institutional investors and hedge funds have recently bought and sold shares of BMY. Vanguard Group Inc. boosted its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after acquiring an additional 2,743,759 shares in the last quarter. State Street Corp lifted its holdings in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after purchasing an additional 1,385,206 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $1,947,272,000. Finally, Ameriprise Financial Inc. increased its stake in Bristol Myers Squibb by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after purchasing an additional 432,158 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Citigroup raised their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Finally, Truist Financial set a $65.00 price target on Bristol Myers Squibb in a report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $61.41.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.